Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA

References

• Yang D, Liu Y, Bai C, et al. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 2020;468:82–87. doi:10.1016/j.canlet.2019.10.009
   PubMed Web of Science ®Google Scholar
• Mayekar MK, Bivona TG. Current landscape of targeted therapy in lung cancer. Clin Pharmacol Ther. 2017;102(5):757–764. doi:10.1002/cpt.810
   PubMed Web of Science ®Google Scholar
• Zhou X, Xu X, Tian Z, et al. Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing. J Cancer Res Clin Oncol. 2020;146(9):2277–2287. doi:10.1007/s00432-020-03284-w
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang L, Yue D, et al. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. Transl Lung Cancer Res. 2020;9(4):1187. doi:10.21037/tlcr-19-664
   PubMed Web of Science ®Google Scholar
• Liu HE, Vuppalapaty M, Wilkerson C, et al. Detection of EGFR mutations in cfDNA and CTCs, and comparison to tumor tissue in non-small-cell-lung-cancer (NSCLC) patients. Front Oncol. 2020;10:2030.
   Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7(1):1–15.
   Google Scholar
• Murtaza M, Dawson SJ, Tsui DWY, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–112. doi:10.1038/nature12065
   PubMed Web of Science ®Google Scholar
• Lin X, Dong W, Lai X, et al. The clinical value of circulating tumor DNA detection in advanced non-small cell lung cancer. Transl Cancer Res. 2019;8(1):170–179. doi:10.21037/tcr.2019.01.20
   PubMed Web of Science ®Google Scholar
• McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–1303. doi:10.1101/gr.107524.110
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568–576. doi:10.1101/gr.129684.111
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519. doi:10.1038/nature11404
   PubMed Web of Science ®Google Scholar
• Collisson E, Campbell J, Brooks A, et al. Comprehensive molecular profiling of lung adenocarcinoma: the cancer genome atlas research network. Nature. 2014;511(7511):543–550.
   PubMed Web of Science ®Google Scholar
• Canale M, Petracci E, Delmonte A, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23(9):2195–2202. doi:10.1158/1078-0432.CCR-16-0966
   PubMed Web of Science ®Google Scholar
• VanderLaan PA, Rangachari D, Mockus SM, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer. 2017;106:17–21. doi:10.1016/j.lungcan.2017.01.011
   PubMed Web of Science ®Google Scholar
• Dees ND, Zhang Q, Kandoth C, et al. Music: identifying mutational significance in cancer genomes. Genome Res. 2012;22(8):1589–1598. doi:10.1101/gr.134635.111
   PubMed Web of Science ®Google Scholar
• van Delft F, Koffijberg H, Retèl V, et al. The validity and predictive value of blood-based biomarkers in prediction of response in the treatment of metastatic non-small cell lung cancer: a systematic review. Cancers. 2020;12(5):1120. doi:10.3390/cancers12051120
   PubMed Web of Science ®Google Scholar
• Tran HT, Lam VK, Elamin YY, et al. Clinical outcomes in non–small-cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors and other targeted therapies based on tumor versus plasma genomic profiling. JCO Precis Oncol. 2021;5(5):1241–1249. doi:10.1200/PO.20.00532
   Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:10.1016/S0140-6736(16)30958-8
   PubMed Web of Science ®Google Scholar
• Schrock AB, Welsh A, Chung JH, et al. Hybrid capture–based genomic profiling of circulating tumor DNA from patients with advanced non–small cell lung cancer. J Thorac Oncol. 2019;14(2):255–264. doi:10.1016/j.jtho.2018.10.008
   PubMed Web of Science ®Google Scholar
• Mascarenhas E, Gelatti AC, Araújo LH, et al. Comprehensive genomic profiling of Brazilian non‐small cell lung cancer patients (GBOT 0118/LACOG0418). Thorac Cancer. 2021;12(5):580–587. doi:10.1111/1759-7714.13777
   PubMed Web of Science ®Google Scholar
• Passaro A, Attili I, Rappa A, et al. Genomic characterization of concurrent alterations in Non-Small Cell Lung Cancer (NSCLC) harboring actionable mutations. Cancers. 2021;13(9):2172. doi:10.3390/cancers13092172
   PubMed Web of Science ®Google Scholar
• Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non–small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31(8):1039. doi:10.1200/JCO.2012.45.3753
   PubMed Web of Science ®Google Scholar
• Zhang XC, Wang J, Shao GG, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019;10(1):1–12. doi:10.1038/s41467-018-07882-8
   PubMed Web of Science ®Google Scholar
• de Bruin EC, McGranahan N, Mitter R, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346(6206):251–256. doi:10.1126/science.1253462
   PubMed Web of Science ®Google Scholar
• Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346(6206):256–259. doi:10.1126/science.1256930
   PubMed Web of Science ®Google Scholar
• Popper HH. Commentary on tumor heterogeneity. Transl Lung Cancer Res. 2016;5(4):433. doi:10.21037/tlcr.2016.08.07
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zheng W, Zeng Q, et al. Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC). Hum Genomics. 2021;15(1):1–10. doi:10.1186/s40246-021-00320-9
   PubMed Web of Science ®Google Scholar
• Hou H, Qin K, Liang Y, et al. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res. 2019;11:5665–5675. doi:10.2147/CMAR.S201513
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JSK, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/JTO.0000000000000033
   PubMed Web of Science ®Google Scholar
• Fang B, Mehran RJ, Heymach JV, et al. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer. 2015;34(3):1–15. doi:10.1186/s40880-015-0028-4
   Google Scholar
• Tang CS, Dattani S, So M, et al. Actionable secondary findings from whole-genome sequencing of 954 East Asians. Hum Genet. 2018;137(1):31–37. doi:10.1007/s00439-017-1852-1
   PubMed Web of Science ®Google Scholar
• Zheng C, Li X, Ren Y, et al. Coexisting EGFR and TP53 mutations in lung adenocarcinoma patients are associated with COMP and ITGB8 upregulation and poor prognosis. Front Mol Biosci. 2020;7:30. doi:10.3389/fmolb.2020.00030
   PubMed Web of Science ®Google Scholar
• Li S, Li L, Zhu Y, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer. 2014;110(11):2812–2820. doi:10.1038/bjc.2014.210
   PubMed Web of Science ®Google Scholar
• Blakely CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49(12):1693–1704. doi:10.1038/ng.3990
   PubMed Web of Science ®Google Scholar
• Gini B, Thomas N, Blakely CM. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J Thorac Dis. 2020;12(5):2883. doi:10.21037/jtd.2020.03.78
   PubMed Web of Science ®Google Scholar
• Mascaux C, Tsao MS, Hirsch FR. Genomic testing in lung cancer: past, present, and future. J Natl Compr Canc Netw. 2018;16(3):323–334. doi:10.6004/jnccn.2017.7019
   PubMed Web of Science ®Google Scholar
• Hoang T, Myung SK, Pham TT, et al. Comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials. J Clin Med. 2020;9(4):1063. doi:10.3390/jcm9041063
   PubMed Web of Science ®Google Scholar
• Jung A, Kirchner T. Liquid biopsy in tumor genetic diagnosis. Dtsch Arztebl Int. 2018;115(10):169. doi:10.3238/arztebl.2018.0169
   PubMed Web of Science ®Google Scholar